German health ministry dodges the innovation issue
This article was originally published in Clinica
Executive Summary
German ministry of health manoeuvring to avoid important issues that will affect industry upon the introduction of the new DRG (Diagnosis Related Groups) system is beginning to frustrate the medical device industry sector. At a meeting last week in Konigswinter, Georg Baum, head of the ministry's department of healthcare provision, was asked to clarify certain issues of relevance to device companies, but failed to satisfy the questioners.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.